James E. Flynn and his fund, Deerfield Management, have disclosed a stake in Audentes Therapeutics Inc (NASDAQ:BOLD), a company that has recently closed its initial public offering. According to a filing with the Securities and Exchange Commission, Flynn and Deerfield hold roughly 1.4 million shares, which account for some 6.68% of the company’s outstanding stock.
Audentes Therapeutics Inc (NASDAQ:BOLD) is a biotechnology company that aims to develop gene therapy for various rare diseases. The company sold 5 million shares at $15 apiece in its initial offering, raising $75 million that it plans to invest in its research work. Among the main conditions it is now studying are X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease. The drug candidates for these three conditions are expected to produce preliminary results from their first trials during the second half of 2017.
Samuel Isaly‘s OrbiMed Advisors had also invested in Audentes Therapeutics Inc (NASDAQ:BOLD) before the initial public offering and was the largest shareholder with a 29.8% stake prior to the offering. Overall, since its inception in 2012, Audentes Therapeutics has raised $135.8 million in equity financing from various venture capitalists and private investors, as well as hedge funds.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Deerfield Management Company||0||1,403,654||0||1,403,654||1,403,654||6.68%|
|Deerfield Mgmt III||0||889,230||0||889,230||889,230||4.23%|
|Deerfield Special Situations Fund||0||514,424||0||514,424||514,424||2.45%|
|Deerfield Private Design Fund III||0||889,230||0||889,230||889,230||4.23%|
|James E. Flynn||0||1,403,654||0||1,403,654||1,403,654||6.68%|
Page 1 of 14 – SEC Filing
Audentes Therapeutics, Inc.
Common Stock, par value $0.00001 per share
July 25, 2016